Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,129 stopped studies mapped to Secondary Malignant Neoplasm and descendants · 91% state a reason
Over the 2,129 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03674827 | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Phase 1 | terminated | Sep 18, 2018 | Pfizer | The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology… | Safety / toxicity |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant…(IMpassion030) | Phase 3 | terminated | Apr 17, 2018 | Hoffmann-La Roche | The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS… | Efficacy / futility |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | N/A | withdrawn | Dec 19, 2019 | Case Comprehensive Cancer Center | Logistics requirements, research cancelled | Other (stated, no rule matched) |
| NCT02037529 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients… | Phase 3 | suspended | Jan 16, 2014 | Academic and Community Cancer Research United | Total enrollment number is being lowered | Enrollment / accrual |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | Phase 2 | withdrawn | Oct 31, 2023 | Case Comprehensive Cancer Center | PI left the institution | Investigator |
| NCT06206278 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer… | Phase 2 | terminated | Jan 16, 2024 | LianBio LLC | Business Reason | Sponsor / business decision |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03853317 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma… | Phase 2 | terminated | Feb 25, 2019 | ImmunityBio, Inc. | Not meeting recruitment goal | Enrollment / accrual |
| NCT04583488 | Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With… | Phase 1 | terminated | Oct 12, 2020 | Johns Hopkins University | PI left institution | Investigator |
| NCT05352542 | GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma | Phase 1 | terminated | Apr 29, 2022 | jianming xu | achieve the proof of concept | Other (stated, no rule matched) |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | Phase 1 | withdrawn | Mar 29, 2024 | Abramson Cancer Center at Penn Medicine | Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280)… | Enrollment / accrual |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B… | Phase 1 / Phase 2 | terminated | Aug 4, 2020 | University of Michigan Rogel Cancer Center | loss of funding | Funding |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | Phase 2 | withdrawn | Feb 6, 2018 | University of Chicago | unable to accrue | Enrollment / accrual |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental… | Phase 2 | withdrawn | Apr 25, 2024 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in… | Phase 1 / Phase 2 | terminated | Dec 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | Due to the rapid shifting of liver cancer disease landscape and the company's adjustment of… | Sponsor / business decision |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of… | Phase 2 | withdrawn | May 3, 2024 | OHSU Knight Cancer Institute | Sponsor withdrawal | Other (stated, no rule matched) |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors,… | Phase 1 | terminated | Apr 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor Decision | Sponsor / business decision |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular… | Phase 1 / Phase 2 | terminated | Dec 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor decision | Sponsor / business decision |
| NCT02649868 | LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of… | N/A | terminated | Jan 8, 2016 | National Institutes of Health Clinical Center (CC) | unavailability of study device | Other (stated, no rule matched) |
| NCT04120246 | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | Phase 1 | suspended | Oct 9, 2019 | Veana Therapeutics | Study placed on hold. | Other (stated, no rule matched) |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Phase 1 | terminated | Mar 15, 2023 | Hoffmann-La Roche | Sponsor decision (not related to safety, efficacy or quality). | Safety / toxicity |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | Phase 1 | withdrawn | Apr 10, 2024 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT00330564 | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have… | Phase 2 | terminated | May 29, 2006 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Sep 26, 2018 | Pfizer | The decision to stop enrollment was due to strategic considerations and not due to any specific… | Safety / toxicity |
| NCT03905889 | A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | Phase 1 | terminated | Apr 5, 2019 | Brown University | Funding withdrawn | Funding |
| NCT02876640 | Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer | Phase 1 | terminated | Aug 24, 2016 | National Cancer Institute (NCI) | Inadequate Accrual Rate | Enrollment / accrual |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors… | Phase 1 / Phase 2 | terminated | Nov 13, 2019 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT04315883 | Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | — | terminated | Mar 20, 2020 | Nemours Children's Clinic | PI left organization and discontinued study | Investigator |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast… | Phase 1 / Phase 2 | terminated | Jun 16, 2021 | ImmunityBio, Inc. | low enrollment | Enrollment / accrual |
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable… | Phase 2 | terminated | Sep 9, 2020 | Aiwu Ruth He, MD | Due to slow accrual. | Enrollment / accrual |
| NCT05572476 | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage…(LURBIMUNE) | Phase 2 | withdrawn | Oct 7, 2022 | Institut Bergonié | Recruitment difficulties, decline in the incidence of the studied pathology, active competitive… | Enrollment / accrual |
| NCT03840967 | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated… | Phase 2 | terminated | Feb 15, 2019 | Shadia Jalal, MD | Due to slow accruals | Enrollment / accrual |
| NCT02542202 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent… | N/A | terminated | Sep 4, 2015 | University of Chicago | due to slow enrollment | Enrollment / accrual |
| NCT03199040 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple… | Phase 1 | terminated | Jun 26, 2017 | Washington University School of Medicine | Drugs/equipment unavailable and insufficient funding | Funding |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects…(SLC-0111-17-01) | Phase 1 / Phase 2 | terminated | Mar 1, 2018 | British Columbia Cancer Agency | Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the… | Enrollment / accrual |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating… | Phase 1 | terminated | Oct 3, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03562507 | Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic…(ERICA) | Phase 2 | terminated | Jun 19, 2018 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT03140176 | Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving…(OPTIMISE) | — | terminated | May 4, 2017 | Pfizer | The study was terminated early due to the inability to recruit the planned number of patients | Enrollment / accrual |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | N/A | withdrawn | Sep 28, 2023 | The University of Tennessee, Knoxville | Unable to recruit participants | Enrollment / accrual |
| NCT02465957 | QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) | Phase 2 | terminated | Jun 9, 2015 | ImmunityBio, Inc. | not stated | Not stated |
| NCT04614766 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat…(SPORE-3) | Phase 1 / Phase 2 | withdrawn | Nov 4, 2020 | David Bushnell | Azedra withdrawn from US market | Other (stated, no rule matched) |
| NCT04429321 | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell… | Phase 1 | terminated | Jun 12, 2020 | Abramson Cancer Center at Penn Medicine | failure to accrue | Enrollment / accrual |
| NCT06377722 | Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or… | Phase 2 | terminated | Apr 22, 2024 | Fundacion Oncosur | The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Aug 23, 2024source: clinicaltrials